skip to content

Vectura Group

16:51 on 20/11/2017

Current Price 91.24p | Bid 91.25p | Ask 91.50p | Change 0.16%

Company Overview

Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25bn. Vectura has seven products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK). Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy.

Stock Details

EPIC VEC
ISIN GB00B01D1K48
Shares in Issue 410,530,184
Market cap £ 574.74m
Sector Pharmaceuticals & Biotechnology
Indices FTSE 250
FTSE SmallCap
UK FTSE All Share
FTSE techMARK Focus Index
FTSE techMARK All Share

Financial Highlights Year Ended 31/03/2014

Turnover £36.50 million
Operating Profit £-6.20 million
Dividend Yield 0.00
Dividend Per Share 0.00
Dividend Cover 0.00
P/E Ratio 116.67
» More Financials

Key Personnel

Chris Blackwell CEO

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Price Summary

Mid Price ? 91.25p
Bid Price ? 91.25p
Ask Price ? 91.50p
Volume ? 753340
Change Today 0.15p
% Change Today 0.16%
Open 90.15p
Previous Close 91.25p
Intraday High 91.85p
Intraday Low 90.00p
52 Week High 200.00p
52 Week Low 138.45p

Intra-Day Chart

More Charts »

Broker Consensus

The above information represents a selection of the views and target prices published in the last 120 days by analysts in individual stocks. It is subject to change without notice and may not necessarily be the view held by Redmayne-Bentley.

Client Area Access

» Secure Login

» Not registered yet?

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.